Considerations for extralabel drug use in calves

Danielle A. Mzyk, Ronette Gehring, Lisa A Tell, Thomas W. Vickroy, Jim E. Riviere, Gail Ragan, Ronald E. Baynes, Geof W. Smith

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Calfhood diseases have major negative economic consequences on beef and dairy operations owing to costs associated with treatment, long-term effects on growth and performance, and death of affected calves. 1-3The number of drugs approved for the treatment of diseased calves by the FDA is limited; however, veterinarians have the authority to administer drugs in an extralabel manner to that class of animals under provisions established by AMDUCA.4 Nevertheless, drug labels that state, “a withdrawal period has not been established for this product in preruminating calves” can cause confusion about whether those drugs can or cannot be administered to young calves. Pharmacokinetic and residue depletion studies for very few drugs have been performed in young calves, and extrapolation of drug WDTs established for adult cattle to calves might not be appropriate or adequate to avoid violative tissue residues, which makes ELDU in calves problematic and potentially difficult to justify. The purpose of this digest is to provide veterinarians with a summary of the considerations for ELDU in both beef and dairy calves as well as calves intended for veal production.

Original languageEnglish (US)
Pages (from-to)1275-1282
Number of pages8
JournalJournal of the American Veterinary Medical Association
Volume250
Issue number11
DOIs
StatePublished - Jun 1 2017

Fingerprint

extra-label drug use
calves
Pharmaceutical Preparations
drugs
Veterinarians
veterinarians
beef
veal calves
dairy calves
pharmacokinetics
drug therapy
Pharmacokinetics
long term effects
Economics
dairies
Costs and Cost Analysis
death
economics
Therapeutics
Growth

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Mzyk, D. A., Gehring, R., Tell, L. A., Vickroy, T. W., Riviere, J. E., Ragan, G., ... Smith, G. W. (2017). Considerations for extralabel drug use in calves. Journal of the American Veterinary Medical Association, 250(11), 1275-1282. https://doi.org/10.2460/javma.250.11.1275

Considerations for extralabel drug use in calves. / Mzyk, Danielle A.; Gehring, Ronette; Tell, Lisa A; Vickroy, Thomas W.; Riviere, Jim E.; Ragan, Gail; Baynes, Ronald E.; Smith, Geof W.

In: Journal of the American Veterinary Medical Association, Vol. 250, No. 11, 01.06.2017, p. 1275-1282.

Research output: Contribution to journalArticle

Mzyk, DA, Gehring, R, Tell, LA, Vickroy, TW, Riviere, JE, Ragan, G, Baynes, RE & Smith, GW 2017, 'Considerations for extralabel drug use in calves', Journal of the American Veterinary Medical Association, vol. 250, no. 11, pp. 1275-1282. https://doi.org/10.2460/javma.250.11.1275
Mzyk, Danielle A. ; Gehring, Ronette ; Tell, Lisa A ; Vickroy, Thomas W. ; Riviere, Jim E. ; Ragan, Gail ; Baynes, Ronald E. ; Smith, Geof W. / Considerations for extralabel drug use in calves. In: Journal of the American Veterinary Medical Association. 2017 ; Vol. 250, No. 11. pp. 1275-1282.
@article{a6ed601cc47949c6928ef6f817d7fe07,
title = "Considerations for extralabel drug use in calves",
abstract = "Calfhood diseases have major negative economic consequences on beef and dairy operations owing to costs associated with treatment, long-term effects on growth and performance, and death of affected calves. 1-3The number of drugs approved for the treatment of diseased calves by the FDA is limited; however, veterinarians have the authority to administer drugs in an extralabel manner to that class of animals under provisions established by AMDUCA.4 Nevertheless, drug labels that state, “a withdrawal period has not been established for this product in preruminating calves” can cause confusion about whether those drugs can or cannot be administered to young calves. Pharmacokinetic and residue depletion studies for very few drugs have been performed in young calves, and extrapolation of drug WDTs established for adult cattle to calves might not be appropriate or adequate to avoid violative tissue residues, which makes ELDU in calves problematic and potentially difficult to justify. The purpose of this digest is to provide veterinarians with a summary of the considerations for ELDU in both beef and dairy calves as well as calves intended for veal production.",
author = "Mzyk, {Danielle A.} and Ronette Gehring and Tell, {Lisa A} and Vickroy, {Thomas W.} and Riviere, {Jim E.} and Gail Ragan and Baynes, {Ronald E.} and Smith, {Geof W.}",
year = "2017",
month = "6",
day = "1",
doi = "10.2460/javma.250.11.1275",
language = "English (US)",
volume = "250",
pages = "1275--1282",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "11",

}

TY - JOUR

T1 - Considerations for extralabel drug use in calves

AU - Mzyk, Danielle A.

AU - Gehring, Ronette

AU - Tell, Lisa A

AU - Vickroy, Thomas W.

AU - Riviere, Jim E.

AU - Ragan, Gail

AU - Baynes, Ronald E.

AU - Smith, Geof W.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Calfhood diseases have major negative economic consequences on beef and dairy operations owing to costs associated with treatment, long-term effects on growth and performance, and death of affected calves. 1-3The number of drugs approved for the treatment of diseased calves by the FDA is limited; however, veterinarians have the authority to administer drugs in an extralabel manner to that class of animals under provisions established by AMDUCA.4 Nevertheless, drug labels that state, “a withdrawal period has not been established for this product in preruminating calves” can cause confusion about whether those drugs can or cannot be administered to young calves. Pharmacokinetic and residue depletion studies for very few drugs have been performed in young calves, and extrapolation of drug WDTs established for adult cattle to calves might not be appropriate or adequate to avoid violative tissue residues, which makes ELDU in calves problematic and potentially difficult to justify. The purpose of this digest is to provide veterinarians with a summary of the considerations for ELDU in both beef and dairy calves as well as calves intended for veal production.

AB - Calfhood diseases have major negative economic consequences on beef and dairy operations owing to costs associated with treatment, long-term effects on growth and performance, and death of affected calves. 1-3The number of drugs approved for the treatment of diseased calves by the FDA is limited; however, veterinarians have the authority to administer drugs in an extralabel manner to that class of animals under provisions established by AMDUCA.4 Nevertheless, drug labels that state, “a withdrawal period has not been established for this product in preruminating calves” can cause confusion about whether those drugs can or cannot be administered to young calves. Pharmacokinetic and residue depletion studies for very few drugs have been performed in young calves, and extrapolation of drug WDTs established for adult cattle to calves might not be appropriate or adequate to avoid violative tissue residues, which makes ELDU in calves problematic and potentially difficult to justify. The purpose of this digest is to provide veterinarians with a summary of the considerations for ELDU in both beef and dairy calves as well as calves intended for veal production.

UR - http://www.scopus.com/inward/record.url?scp=85018376127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018376127&partnerID=8YFLogxK

U2 - 10.2460/javma.250.11.1275

DO - 10.2460/javma.250.11.1275

M3 - Article

VL - 250

SP - 1275

EP - 1282

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 11

ER -